The partial androgen insensitivity syndrome occurs in 46,XY subjects with phenotypes ranging from perineoscrotal hypospadias with cryptorchidism and micropenis (mild undervirilisation) (Arch Dis Child 1993; 68: 453-457) androgen binding, the central domain (exons B and C) consists of two zinc finger-like elements responsible for DNA binding, and the less well characterised N terminal domain (exon A) has a role in transcriptional activation by the receptor.78
Abstract
The partial androgen insensitivity syndrome occurs in 46,XY subjects with phenotypes ranging from perineoscrotal hypospadias with cryptorchidism and micropenis (mild undervirilisation) to citoromegaly and partial labial fusion (marked undervirilisation). Within an affected family, wide variation in the degree of genital ambiguity between individuals can be seen. Two cousins of a previously reported subject who had severe genital ambiguity and partial androgen insensitivity were investigated. Neither of the cousins had genital abnormalities as marked as the index case, who also had qualitatively abnormal androgen binding and two mutations of the androgen receptor gene. Despite marked phenotypic differences between the index case and his cousins, similar androgen binding and the same androgen receptor mutations were shown in the cousins. Furthermore, one of the androgen receptor gene mutations has been shown in the mother and sister of one of the boys indicating that they are carriers. Thus phenotypic variation in families affected by partial androgen insensitivity is dependent on factors other than abnormalities of the androgen receptor gene alone. Although carrier status in partial androgen insensitivity can be determined, the severity of genital abnormalities in an affected offspring cannot be reliably predicted. (Arch Dis Child 1993; 68: 453-457) androgen binding, the central domain (exons B and C) consists of two zinc finger-like elements responsible for DNA binding, and the less well characterised N terminal domain (exon A) has a role in transcriptional activation by the receptor.78
The androgen receptor gene mutations in a subject from a family with partial androgen insensitivity syndrome with seven affected males have been described.9 This subject had a point mutation (single nucleotide substitution) in exon E of the androgen binding domain of the androgen receptor gene resulting in a change from a tyrosine to a cysteine at amino acid 761. In addition, the subject had a shortening of the hypervariable polyglutamine region of exon A to 12 residues, which is at the lower end of the normal range defined for a number of groups.'0 Expression studies of the mutant receptor showed that the two mutations interacted to cause the qualitative abnormalities in androgen binding seen in this patient. 9 We have investigated two further subjects from this kindred and outline their clinical features, androgen binding studies, and androgen receptor gene analysis. Neither subject has a clinical phenotype as severe as the subject described previously. In addition, we have investigated the carrier status ofthe mother and sister of one of the affected subjects.
Subjects and methods Figure 1 shows the family pedigree. Figure 3 Sequencing ofexon E ofthe androgen receptor gene in subject III sequencing abnormality was detected in exon E in subjects III-I, III-3, and nucleotide is indicated by an asterisk. The resultant change in amino acid is 6 (Ala=alanine, Phe=phenylalanine, Tyr=tyrosine, Cys=cystaine, Leu=l-Met=methionine).
binding assays in subjects III-1 a two subjects had a qualitative defe binding shown by the high Kd vali androgen binding affinity) and the binding. There was no quantitativ of androgen binding. These resi that the two boys had an abnor receptor. Despite being performe( laboratory, androgen binding stud III-6 showed similar androgen b malities to those of subjects III-1 subject III-6 the qualitative abnor were thermolability when the assa was increased from 30 to 41°C an( dissociation rate of androgen from The dissociation constant was not As it was probable thdiiiember, kindred would share the same and. gene abnormalities, exons A and the abnormalities in subject III-( ined first.9 Exon E was examine subjects (III-1, III-3, and III-6) 1 presence of a mutation is indicate the mobility of denatured PCR si run on a non-denaturing gel. Figu presence of an SSCP band shi fragments from subjects III-1, II The band shift is the same in all 1 suggesting that the mutation is fl abnormality was detected readily sets of electrophoresis condii sequencing ofexon E in subjects I] A C G T III-6 confirmed the presence of a point mutation (adenine to guanine) causing an amino acid change from tyrosine to cysteine at amino acid 761 (fig 3) . The mutations were sequenced on the two strands. The region of exon A encoding q 7 the polymorphic glutamine repeat was also sequenced in subjects III-1, III-3, and III-6 and W _ in each instance 12 glutamine residues were _ found, which is at the lower limit of that defined for the normal population.'0 No other mutations := were found in these two exons in any of the -_-*-subjects. In an attempt to determine a cause for the phenotypic variability in this family, the rest of the androgen receptor gene was also screened for mutations in the three subjects. No other _i _ SSCP abnormalities were detected in any part of the gene, suggesting that there was no other abnormality of the androgen receptor gene. Figure 4 summarises the androgen receptor gene abnormalities found in subjects III-1, III-3, and Mutant III-6.
-1. The same Figure 5 shows the results of SSCP screening III-6. The altered of exon E for detection of carrier status. The also shown SSCP banding pattern of a normal control ucine, showed two bands. In addition, the PCR fragment from subject III-1 also showed two bands, nd III-3. The one of which migrated at a different rate to the ct in androgen control DNA. Exon E PCR products from ue (that is, low subject II-3 (mother) and III-2 (sister) had androgen production at a critical stage during in utero genital development has contributed to the spectrum of genital abnormalities seen in this family.
Single strand conformation polymorphism is a simple and reliable technique for the demonstation of androgen receptor gene abnormalities in carriers, and has allowed rapid analysis of DNA from female relatives of one of the affected boys. In this way we have shown that the subject's mother and sister are heterozygous carriers of the mutant allele. Other studies have also reported analysis of carrier detection in complete and partial androgen insensitivity syndrome, using analysis of the hypervariable polyglutamine region encoded by exon A9 or analysis of a Hind III restriction fragment length polymorphism associated with the androgen receptor gene.7I Thus once the androgen receptor gene abnormality in an index case has been established, it is possible to offer reliable assessment of carrier status, genetic counselling, and prenatal diagnosis. 9 Dr Ichinose and his colleagues studied 10 patients aged between 18 and 55 years with asthma. In a double blind, crossover trial each patient received inhaled bradykinin in gradually increasing doses beginning 25 minutes after the inhalation of either FK-224 or placebo. The bronchoconstrictor response as shown by the fall in specific airway conductance (sGaw) measured by whole body plethysmography was less severe after FK-224. The mean cumulative concentration of bradykinin needed to produce a 35% fall in sGaw was 5-3 1.g/ml after placebo and 40 iig/ml after FK-224 (p<O-OOl). Coughing induced by the inhalation of bradykinin was prevented by pretreatment with FK-224.
The results give support to the hypothesis that neurogenic inflammation mediated by tachykinins might be involved in the asthmatic process and tachykinin antagonists could prove to be useful in the treatment of asthma. 
